Results 191 to 200 of about 57,191 (243)
Some of the next articles are maybe not open access.
ABP 980: A Trastuzumab Biosimilar
BioDrugs, 2018ABP 980 (KANJINTI™) is a biosimilar of the reference anti-HER2 antibody trastuzumab. In the EU, ABP 980 is approved for use in all indications for which reference trastuzumab is approved, including HER2-positive early breast cancer, metastatic breast cancer and metastatic gastric cancer.
openaire +2 more sources

